Migliorini Filippo, Schäfer Luise, Pilone Marco, Bell Andreas, Simeone Francesco, Maffulli Nicola
Department of Orthopaedic and Trauma Surgery, Academic Hospital of Bolzano (SABES-ASDAA), 39100, Bolzano, Italy.
Department of Orthopaedic and Trauma Surgery, Eifelklinik St.Brigida, 52152, Simmerath, Germany.
Arch Orthop Trauma Surg. 2024 Dec 18;145(1):68. doi: 10.1007/s00402-024-05614-w.
The present meta-analysis compared the efficacy of intra-articular hyaluronic acid (HA) injections in patients with early to mild knee osteoarthritis (OA) (Kellgren Lawrence I-II) versus other commonly injected biologically active compounds using patient-reported outcome measures (PROMs). The outcomes of interest were the visual analogue scale (VAS) and the Western Ontario McMaster Osteo-Arthritis Index (WOMAC) scores.
This study was conducted according to the 2020 PRISMA statement. In April 2024, PubMed, Web of Science, Google Scholar, and Embase were accessed without time constraints. All the randomised controlled trials (RCTs) investigating the efficacy of intra-articular HA injections in the early stages of knee OA were accessed. Data concerning the VAS, WOMAC, and related subscales were collected at baseline and the last follow-up. Only studies clearly stated the degrees of advancement of OA using the Kellgren-Lawrence scoring system were used.
The literature search resulted in four RCTs (390 patients). The mean length of the last follow-up was 7.5 ± 3.0 months. 72.3% (282 of 390) of the patients were women. The mean age of the patients was 58.1 ± 3.2 years, and the mean BMI was 27.3 ± 3.2 kg/m. At the last follow-up, no difference was found between HA and the control group in VAS, WOMAC, and related subscales.
In patients with early to mild knee osteoarthritis, the current level of evidence suggests that intra-articular injections using HA performed similarly to other biologically active compounds commonly injected in the knee joint for a minimum of three months.
Level I, meta-analysis.
本荟萃分析比较了关节腔内注射透明质酸(HA)对早期至轻度膝关节骨关节炎(OA)(凯尔格伦-劳伦斯 I-II 级)患者与其他常用注射生物活性化合物的疗效,采用患者报告的结局指标(PROMs)。感兴趣的结局指标是视觉模拟量表(VAS)和西安大略和麦克马斯特大学骨关节炎指数(WOMAC)评分。
本研究按照2020年PRISMA声明进行。2024年4月,无时间限制地检索了PubMed、科学网、谷歌学术和Embase。纳入了所有研究关节腔内注射HA对早期膝关节OA疗效的随机对照试验(RCT)。在基线和末次随访时收集有关VAS、WOMAC及相关子量表的数据。仅使用明确采用凯尔格伦-劳伦斯评分系统说明OA进展程度的研究。
文献检索得到4项RCT(390例患者)。末次随访的平均时长为7.5±3.0个月。72.3%(390例中的282例)患者为女性。患者的平均年龄为58.1±3.2岁,平均体重指数为27.3±3.2kg/m。在末次随访时,HA组与对照组在VAS、WOMAC及相关子量表方面未发现差异。
对于早期至轻度膝关节骨关节炎患者,目前的证据水平表明,关节腔内注射HA与其他常用于膝关节的生物活性化合物的效果相似,至少持续三个月。
I级,荟萃分析。